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Summary 
Becker muscular dystrophy is an X-linked disease due to mutations of the dystrophin gene. We 
now show that neuronal-type nitric oxide synthase (nNOS), an identified enzyme in the dys- 
trophin complex, is uniquely absent from skeletal muscle plasma  membrane in many human 
Becker patients  and  in  mouse  models  of dystrophinopathy.  An  NH2-terminal  domain  of 
nNOS  directly interacts with cxl-syntrophin but  not with  other proteins  in  the  dystrophin 
complex analyzed. However, nNOS does not associate with cll-syntrophin on the sarcolemma 
in transgenic mdx mice expressing truncated dystrophin proteins. This suggests  a ternary inter- 
action of nNOS,  ~l-syntrophin, and the central domain of dystrophin in vivo, a conclusion 
supported by developmental studies in muscle. These data indicate that proper assembly of the 
dystrophin complex is dependent upon the structure of the central rodlike domain and have 
implications for the design ofdystrophin-containing vectors for gene therapy. 
M 
utations  of the  X-linked  dystrophin  gene  are  the 
most common cause of inherited muscular dystro- 
phy and affect ~1:3,500 male births (1). Duchenne muscu- 
lar dystrophy (DMD) I, the more common and more severe 
form of the disease, is associated with mutations that lead to 
an absence of dystrophin protein in muscle (2, 3). A clini- 
cally milder  disease,  Becket muscular  dystrophy  (BMD), 
accounts  for ~20%  of cases  and  often involves deletions 
within the rodlike central domain of dystrophin (4). Mus- 
cle  dystrophin  levels  are  often  nearly  normal  in  BMD, 
which  can  preclude  diagnosis  by  immunohistochemical 
analysis ofdystrophin (5). 
Dystrophin is a large intracellular protein containing sev- 
eral defined sequence motis  (6). An NH2-terrninal cx-acti- 
nin-like domain binds to F-actin (7), and is followed by a 
large rod domain that shares  sequence homology with the 
structural  repeats  in  spectrin.  The  COOH  terminus  is 
unique to dystrophin and related proteins, and this region 
~  Abbreviations used in this paper: oe-BGT,  alpha  bungaro-toxin;  AChR, ace- 
tylcholine  receptor;  BMD, Becket  muscular dystrophy;  DMD, Duchenne 
muscular dystrophy; GST, glutathione-S-transferase;  nNOS, neural-type 
nitric oxide synthase; NO, nitric oxide; PH, pleckstrim  homology. 
direcdy binds to a glycoprotein complex in skeletal muscle 
(8-10).  The  structural  dystrophin-associated  complex in- 
cludes intracellular proteins, syntrophins (11), as well as in- 
tegral  membranes  proteins,  the  dystroglycans  (12)  and 
sarcoglycans; the absence of dystrophin in  DMD  causes  a 
disruption of this complex (13). These interactions suggest 
a structural role for dystrophin, physically linking the extra- 
cellular matrix to the muscle cytoskeleton (14).  In support 
of this  model,  genetic  mutations  in  components  of the 
sarcoglycan complex can cause autosomal recessive muscu- 
lar dystrophy (15-18). 
Restoration of a functional dystrophin molecule to mus- 
cle represents a primary goal for therapy. To better under- 
stand mechanisms for assembly of the dystrophin complex 
and to identify potential constructs for gene therapy, frag- 
ments of dystrophin have been targeted to skeletal muscle 
of transgenic  mdx  mice,  which  lack  endogenous  dystro- 
phin.  Replacement with either a full-length dystrophin, a 
COOH-terminal construct encoding 71 kD of dystrophin, 
Dp71, or a dystrophin minigene, lacking a large portion of 
the central spectrinlike repeats, restores the structural dys- 
trophin complex to muscle. P..eplacement with full-length 
dystrophin corrects muscular dystrophy in mdx mice (19). 
Despite  apparent  restoration  of the  dystrophin  complex, 
mdx mice targeted with Dp71, still display severe muscular 
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have a very. mild disease phenotype  (20,  21).  These  results 
indicate  that  all  components  of the  dystrophin membrane 
cytoskeleton  are  needed  to  completely prevent  symptoms 
of muscular dystrophy. 
In addition  to their cytoskeletal role,  dystrophin and as- 
sociated proteins have been implicated in specific signaling 
functions of the junctional and extrajunctional sarcolemma. 
The  dystrophin-related  protein,  utrophin,  is  concentrated 
at neuromuscular endplates  and is implicated in acetylcho- 
line receptor (AChl<) clustering, ot-dystroglycan binds with 
high affinity to agrin and laminin suggesting that  the  dys- 
trophin-associated  complex  may  serve  as  a  link  between 
the  extracellular  matrix  and  intracellular  events  that  help 
form AChR. clusters  (22,  23).  Signaling by the  dystrophin 
complex may be mediated in part by nitric  oxide  (NO),  a 
messenger  molecule  in  muscle  that  can  regulate  myocyte 
development  (24),  AChR. function  (25),  and  muscle  con- 
tractility (26). NO is formed in skeletal muscle by the neu- 
ronal-type nitric oxide synthase (nNOS)  that is enriched at 
the sarcolemma of fast twitch muscle fibers in rodents  (26) 
and  in  both  fast  and  slow  twitch  fibers  in  primates  (27). 
R.ecent  studies  identify  nNOS  as  a  nonstructural  compo- 
nent of the dystrophin complex (28).  Furthermore,  nNOS 
is absent from skeletal muscle sarcolemma of mdx mice and 
in  DMD  (28).  Biochemical  studies  in  vitro  demonstrate 
that  the  NH 2 terminus  of nNOS,  which  contains  a  PDZ 
protein  motif,  directly binds  to a similar motif in cel-syn- 
trophin  (29);  furthermore,  nNOS  and  od-syntrophin 
coimmunoprecipitate from muscle extracts. Direct binding 
of nNOS to dystrophin or other associated proteins has not 
yet been demonstrated. 
DMD  and  mdx  mice  show  primary  dystrophin  defi- 
ciency and  secondary deficiencies  of sarcoglycans, dystro- 
glycans, syntrophins,  and nNOS.  BMD in humans,  due to 
abnormal dystrophin, generally retains dystrophin-associated 
proteins,  though nNOS  has not been evaluated.  We now 
show that nNOS is properly restored to the plasma mem- 
brane in transgenic mdx mice expressing full-length human 
dystrophin  but  is  selectively  absent  from  skeletal  muscle 
membranes  in  mdx  mice  expressing  either  Dp  71  (DMD 
phenotype)  or a dystrophin minigene lacking many of the 
spectrinlike repeats (very mild BMD phenotype). Dyslocal- 
ization of nNOS in the transgenic mouse nmdels is associ- 
ated  with  disruption  of the  normal nNOSAxl-syntrophin 
interaction.  In  human  biopsies,  we  note  that  loss  of sar- 
colemmal nNOS is commonly observed in BMD. In some 
patients,  lacking as little  as three  exons in  the  spectrinlike 
domain  of dystrophin,  the  absence  of sarcolemmal  nNOS 
represents the only identified immunohistochemical abnor- 
mality. 
Materials  and Methods 
Antibodies.  The  following  primary  antibodies  were  used: 
nNOS polyclonal raised against homogenous nNOS protein pu- 
rified from rat cerebellum (30), nNOS monoclonai (Transduction 
Labs,  Lexington,  KY),  od-syntrophin  polyclonal,  syntrophin 
monoclonal (31), dystrophin monoclonal (Signna Chemical  Co., 
St.  Louis,  MO),  [3-dystroglycan  monoclonal,  utrophin  mono- 
clonal,  and a-sarcoglycan rnonoclonal  (Novacastra  Laboratories 
Ltd., Newcastle upon Tyne, UK). 
lmmunofluorescence.  Unfixed  skeletal  muscle  samples  were 
flash frozen in liquid nitrogen-cooled isopentane,  sectioned on a 
cryostat  (10  Ixm), and melted directly onto glass slides. Sections 
were then postfixed  in 2% paraformaldehyde in PBS or cold ace- 
tone. Tissues were "blocked" in PBS containing 1% normal goat 
sermn.  Primary antibodies  were diluted in blocking reagent  and 
were applied to sections overnight at 4~  For indirect immuno- 
fluorescence,  secondary goat anti-rabbit FITC-, or donkey anti- 
mouse Cy-3-conjugated antibodies  were  used  according to the 
manufacturer's specifications  (The Jackson Laboratory, Bar  Har- 
bor, ME;  1:200)_ Cy-3-conjugated 0~-BGT (kindly  provided by 
Peter  Sargent,  University of California,  San  Francisco)  was  di- 
luted together with  the  secondary antibody t-or double  labeling 
motor endplates. 
Tissue Extraction1 and Western Blot Analysis.  Mouse  quadriceps 
skeletal  nmscle  was  homogenized  in  1(1  volumes  (wt/vol)  of 
buffer  A  (25  mM  Tris-HC1,  pH  7.4,  100  mM  NaCl,  1 mM 
EDTA, l mM EGTA, and 1 mM PMSF), and heavy, microsomes 
were prepared by a standard  protocol with minor modifications. 
Nuclei were pelleted  by centrifugation at  1,000 ,~.  The superna- 
tant  was  then  centrifuged at  20,000 ,~,  yielding supernatant  S~. 
The resulting  heavy microsomal pellet  was resuspended  in buffer 
A containing 500 mM NaC1,  incubated for 30 rain  at 4~  with 
agitation,  and  centrifuged at  15,000  ,~,  yielding supernatant  S,. 
This resulting  pellet  was resuspended  in buffer  A containing 5~0 
mM NaC1 plus 0.5% Triton X-100, incubated for 30 mm at 4o(  ", 
with agitation,  and centrifuged at  15,000 ,~, yielding supernatant 
$3 and a final pellet P. 
Tissue  extracts  were  resolved  by  SDS-PAGE  (7.5% acryla- 
mide)  and proteins  were  transferred  to  polyvinylidene fluoride 
membranes  (hnmobilon-P;  Millipore  Corp.,  Bedford,  MA). 
Membranes were incubated  overnight  with primary antisera diluted 
in Tris-HC1 buffered saline containing 1% BSA, hnnmnoreactive 
bands  were visualized  by the  enhanced chemiluminescence sys- 
tem  according to  the  manufacturer's  specifications  (Amersham 
Corp., Arlington Heights,  ILl. 
Immunoprecipitation.  Polyctonal antibodies  (1  ~g)  to od-syn- 
trophin or noninmmne serum were added to 0.5-ml aliquots  of 
solubilized skeletal  muscle  membranes from wild-type mouse 
(1 mg/ml) or total solubilized nmscle extract from mdx mouse 
(2 mg/ml), and samples were incubated on ice  fbr  1 h.  Protein 
A-Sepharose (50 p,1) was used to precipitate  antibodies.  Protein A 
pellets were washed  three times with buffer containing I{t0 mM 
NaCI and 1% Triton X-100. Immunoprecipitated proteins  were 
denatured with loading buffer and resolved by SDS-PAGE. 
Fusion P~vtein Aflb~ity Chromatq~raphl,.  A  thsion  protein  of 
glutathione-S-transferase  (GST) fused to the first 299 amino acids 
of nNOS  was  expressed  in  Escheridzia coil and purified  on  glu- 
tathione  Sepharose  beads  as  described  (28). Solubilized  skeletal 
muscle  membranes were incubated with control ((;ST) or GST- 
nNOS  (1-299)  beads.  Samples  were loaded into disposable  col- 
unms washed with 5(1 volumes of buffer containing 0.5% Triton 
X-I(10 plus 3(}(I mM NaC1, and proteins were eluted with 150 p,1 
of SDS-PAGE loading buffer. 
Characterization qfHumal~ Tissues.  All human muscle  biopsies 
were obtained for diagnostic  purposes  (dystrophin  analysis), and 
were flash frozen in isopentane  cooled in liquid nitrogen. Patients 
were evaluated  for dystrophin expression by immunofluorescence 
and Western blotting as described  (32, 33). Mutation detection in 
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scribed. Mutation detection in or  (adhalin) was done 
by RT-PCR and single strand conformation polymorphism, with 
aberrant conformers sequenced as previously described (34);  one 
patient was  homozygous for an Arg77Cys mutation whereas an- 
other was a compound heterozygote, Leu31Pro and Arg284Cys. 
All biopsies used in  this study were  deemed to  be  of excellent 
preservation based on hematoxylin and eosin staining of cryosec- 
tions. 
Results 
Previous studies  suggest  that  association of nNOS  with 
the  dystrophin  complex  is mediated  by  direct binding of 
the  NH2-terminus  of nNOS  to  the  PDZ  domain  of c~l- 
syntrophin (29). However, during skeletal muscle develop- 
ment, we found a dissociation between nNOS and oel-syn- 
trophin  localization  in  muscle.  Throughout  postnatal  rat 
development, otl-syntrophin was present at extrajunctional 
sarcolemma and was particularly enriched at neuromuscular 
endplates  (Fig.  1).  By contrast, at postnatal day 3  (P3)  and 
P7,  nNOS  was  observed  only  at  extrajunctional  sarco- 
lemma.  Enrichment  of nNOS at neuromuscular  endplates 
did not become apparent until P12,  coincident with accu- 
mulation  of dystrophin  at  endplates.  Utrophin  was  en- 
riched at endplates in all stages evaluated. 
We  compared  nNOS  and  otl-syntrophin expression  in 
Figure 1.  Localization of nNOS and other dystrophin-associated  proteins during postnatal development. Adjacent sections of postnatal rat quadriceps 
muscle were stained for dystrophin, nNOS, oe-BGT, and utrophin, and nearby sections were stained for otl-syntrophin and cx-BGT. Dystrophin and 
uNOS stained extrajunctional sarcolemma at P3 and P7 and both became concentrated at neuromuscular endplates at P12 and P60. otl-syntrophin was 
present at extrajunctional sarcolemma and was enriched at neuromuscular endplates at all ages evaluated. Utrophin staining was restricted to neuromuscu- 
lar endplates. 
611  Chao et al, Figure 2.  Localization of nNOS and ~xl-syntrophin in transgenic mdx mice.  Cryosections from mouse quadriceps were  double labeled for either 
nNOS or ~xl-syntrophin and cr  Immunofluorescent staining showed that nNOS in wild-type mouse was expressed at extrajunctional sareolemma of 
a subset of fibers and was enriched at all neuromuscular endplates, nNOS was absent from junctional and extrajunctional sarcolemma in mdx mice. nNOS 
staining in mdx transgenic mice expressing full-length dystrophin (full-dys) or truncated dystrophin lacking the COOH-termina1330 nucleotides (A331)) 
resembled that of  wild-type mice. mdx mice expressing  dystrophin-lacking  exons 17--48 (AEXON 17-48  mini-dys) or the COOH-terrmna171  kD of dystro- 
phin Dp7l lacked nNOS staining at sarcolemma, similar to nontransgenic mdx mouse, otl-syntrophin occurred at extrajunctional sarcolemma a~ad was 
concentrated at neuromuscular endplates in wild-type mice and was restricted to the endplates in mdx mouse, cd-syntrophin expression was restored to 
sarcolemma in the four transgenic mdx mouse lines expressing different portions of the dystrophin gene. 
skeletal  muscle  of wild-type,  mdx,  and various  transgenic 
mdx mice  (Fig.  2)  that express mutant forms  of dystrophin 
(8,  9,  19-21,  35).  As  previously  reported,  otl-syntrophin 
was absent from extrajunctional sarcolemma of mdx mouse, 
but remained at  neuromuscular endplates  (31,  36).  nNOS 
was absent from both junctional and extrajunctional sarco- 
lemma  of mdx  mouse.  Four lines of mdx  transgenic mice 
were evaluated. These previously described lines express ei- 
ther full-length dystrophin  (line 862CAA  [201),  or various 
truncated dystrophins, lacking either the 330 nucleotides of 
exons 71-74 near the COOH-terminus  (A330  [35]),  lack- 
ing  exons  17-48  of  the  spectrinlike  motif  (AE17-48; 
CVBA line 12142  [20]), or lacking all but the COOH-ter- 
minal  71  kD  (Dp71;  MCA-1  [8,  9]).  As  previously  re- 
612  Sarcolemmal Nitric Oxide Synthase in Becker Muscular Dystrophy Figure  3.  Subcellular distribution of nNOS in transgenic mdx mouse. 
Mouse  quadriceps  skeletal  muscle  homogenates  were  sequentially  ex- 
tracted with buffers containing 100 mM NaC1  (S1),  500 mM NaCI ($2), 
and 0.5% Triton X-100 ($3), leaving an insoluble cytoskeletal pellet (P). 
(A)  Western blotting indicated that nNOS  was enriched in membrane- 
associated and pellet fractions in wild-type mouse (lanes  1) and transgenic 
mdx mice expressing full-length dystrophin (lanes 4). In mdx mouse (lanes 
2)  and Dp71  transgenic mdx mouse (lanes  3),  nNOS was fully  extracted 
by 500 mM NaCI  and was absent from membrane-associated and cyto- 
skeletal  fractions.  (B  and  C)  A  similar fractionation was  performed on 
muscle homogenates from wild-type nmuse (lanes  1), mdx mouse express- 
ing dystrophin-lacking exons  17-48  (lanes  2),  or mdx  mouse expressing 
fill-length dystrophin (lanes  3).  (B) nNOS was absent from membrane- 
associated ($3)  and  cytoskeletal pellet (P)  in  mdx  mouse expressing the 
truncated dystrophin. (C)  R.eprobing the blot shows that od-syntrophin 
had a generally similar fractionation in nmscle from all three mice lines. 
ported,  oLl-syntrophin  expression  was  restored  to  junc- 
tional  and  extrajunctional  sarcolemma  in  each  of the  four 
transgenics.  By  contrast,  nNOS  was  restored  to  the  sarco- 
lemma  only  by  full-length  dystrophin  and  the  A330  mu- 
tant. 
Figure 4.  Selective interaction ofnNOS and od-syntrophin. Crude sol- 
ubilized membranes from mouse quadriceps were titrated with NaOH to 
pH 11, to dissociate the dystrophin complex, and were neutralized to pH 7.4 
with  1 M  Tris-HC1.  Native and dissociated  (&~soc) preparations  were incu- 
bated with agarose beads linked to either GST or GST fused to the first 299 
anfino acids ofnNOS (G-NOS).  After extensive washing, beads were eluted 
with loading buffer and proteins were resolved by SDS/PAGE. (A) West- 
em blotting showed that txl-syntrophin was selectively retained by G-NOS 
beads in  both  native and  dissociated  preparations.  Reprobing the same 
blot with (B) dystrophin or (C) ot-sarcoglycan  revealed that G-NOS beads 
retained these proteins from native protein preparations. However, after 
dissociation of the complex, neither dystrophin nor ot-sarcoglycan bound 
to G-NOS. The 55-kD band observed in input lanes from r 
blot appears to be mouse IgG and was reactive with the secondary anti- 
body used for Western blotting. (D) Coimmunoprecipitation ofnNOS with 
otl-syntrophin from wild-type and mdx mouse skeletal  muscle. Total sol- 
ubilized extract from mdx (lanes  1 and 2) or solubilized membranes from 
wild-type (lanes 3 and 4) mouse quadriceps were immunoprecipitated with 
an antibody to od-syntrophin (lanes  1 and 3) or nonimmune serum (lanes 
2 and 4). Western blotting indicates that nNOS was specifically  coimmu- 
noprecipitated with oel-syntrophin from mdx and wild-type extracts. 
613  Chao et al. Table 1.  Sarcolemmal  Expression of nNOS, Dystrophin, and Syntrophin in BMD 
Imunofluorescence at sarcolenlnla 
Exons deleted 
Diagnosis  (mutation)  Age at biopsy  nNOS  Dystrophin  Syntrophin 
Normal  53  + + + +  + + + +  + + + + 
Normal  41  + + + +  + + + +  + + + + 
Mild BMD  45-47  30  0  + + + +  + + + + 
Mild BMD  52  29  + + +  + + + +  + + + + 
Mild BMD  45-48  8  +  + + + +  + + + + 
Int. BMD  3-6  13  +  +++  ++++ 
Int. BMD  10-42  24  0  + + + +  + + + + 
Int. BMD  13-41  12  ++  +++  ++++ 
Int. BMD  45  23  0  +  + + 
Sev. BMD  8  10  0  +  + + + 
Sev. BMD  3-7  7  0  +  + + + 
Sev. BMD  45-47  t0  0  +++  ++++ 
Sev. BMD  51-52  9  (I  +  + + + 
a-sarcoglycanopathy  (L31P/R284C)  ll  + + + +  + + + +  + + + + 
{x-sarcoglycanopathy  (P,77C/P,.77C)  8  + + +  + + +  + + + + 
Human  muscle biopsies were labeled by immunofluorescence. Sarcolemmal labeling was blindly evaluated by three observers from {) to  + + + +. 
Variation between observers never varied by more than one +, and for those cases, the majority score is reported, bit., intermediate; Sev., severe. 
Biochemical studies confirmed that nNOS  did not asso- 
ciate with sarcolemma in mdx mice or transgenic mdx mice 
expressing either Dp71  or ~E17-48.  In wild-type and mdx 
transgenic  mice  expressing  full-length  dystrophin,  nNOS 
was enriched in membrane-associated and cytoskeletal frac- 
tions,  whereas  in  mdx,  Dp71,  and  ZXE17-48  lines,  nNOS 
was  present only in soluble fractions of muscle.  As previ- 
ously  reported,  ed-syntrophin  occurred  in  sarcolemmal 
fractions of all four lines of transgenic mdx mice evaluated 
(Fig. 3, and data not shown). 
Whereas these studies are consistent with the model that 
association of nNOS with ed-syntrophin in vivo requires a 
full-length dystrophin, direct binding ofnNOS to the rodlike 
domain  of  dystrophin  or  another  dystrophin-associated 
protein could also explain the data.  Previous studies dem- 
onstrate that the NH2-terminal domain ofnNOS is necessary 
and sufficient for interaction with  the  dystrophin complex 
(28).  We  therefore  evaluated  interaction  of dystrophin- 
associated proteins with a  purified fusion protein contain- 
ing the first 299 amino acids ofnNOS.  As previously dem- 
onstrated, a Sepharose column linked to this fusion protein 
selectively retained  several components  of the  dystrophin 
complex from crude skeletal muscle extracts. To determine 
which  components  directly interact with  nNOS  in  vitro, 
we dissociated the dystrophin complex by briefly adjusting 
the  pH  of muscle  extracts  to  11  and  then  repeating  the 
binding assays immediately after neutralizing the  extracts. 
Previous studies (37) have demonstrated that this procedure 
reversibly dissociates dystrophin  from  associated proteins. 
After dissociation of the  complex,  ed-syntrophin  contin- 
ued  to  interact  with  the  nNOS  column  but  dystrophin, 
tx-sarcoglycan, and  [3-dystroglycan were  not retained (Fig. 
4, A-C and data not shown). 
To further verify that nNOS  directly interacts with syn- 
trophin  in  vivo,  we  conducted  inmmnoprecipitation  ex- 
periments in mdx mouse  (Fig. 4/7)). A  polyclonal antibody 
to ed-syntrophin specifically coimnmnoprecipitated a small 
amount  of nNOS  from  extracts  of mdx  skeletal  nmscle. 
nNOS was more efficiently coinmmnoprecipitated with e~ 1- 
syntrophin from solubilized membranes of wild-type mouse 
as previously shown (29). 
We next asked whether mutations in the  NH2-terminal 
or rodlike domains  of dystrophin that  cause BMD  in  hu- 
mans  were  associated with  altered localization of nNOS. 
We immunohistochemically evaluated nNOS  and txl-syn- 
trophin  expression in  12  BMD  patients  with  molecularly 
defined  deletions  in  the  dystrophin  gene.  Immunohis- 
tochemical  expression  of nNOS,  dystrophin,  and  syntro- 
phin were assessed blindly. Loss ofsarcolemmal nNOS, but 
not  cd-syntrophin  expression was  associated with  Becker 
phenotype (Table 1). Some of the patients, with mild to in- 
termediate  disease, showed  reduced but  detectable nNOS 
614  Sarcolemmal Nitric Oxide Synthase in Becker Muscular Dystrophy Figure 5.  nNOS is absent from skeletal muscle sarcolemma in certain patients with BMD. Skeletal muscle cryosections  from human biopsies were im- 
munostained with monoclonal antibodies to dystrophin, syntrophin, ot-sarcoglycan,  or polyclonal antibody nNOS. All four antibodies showed sarcolem- 
mal staining in normal patients and essentially  no sarcolemmal  labeling in patients with DMD. In two patients with BMD, due to loss of exons 45-47 or 
10-42 of dystrophin, immunofluorescent labeling for dystrophin, syntrophin, and ot-sarcoglycan  was detected at the membrane. By contrast, nNOS sar- 
colemmal staining was undetectable in these two BMD patients, nNOS labeling was present in a patient with ot-sarcoglycan  deficiency. 
staining ofsarcolemma. In several patients, loss ofsarcolem- 
mal nNOS occurred despite apparently normal assembly of 
other  components  of the  dystrophin-associated glycopro- 
tein  complex  (Fig.  5).  By  contrast,  we  found  that  nNOS 
expression was  intact in  two  patients  with  primary et-sar- 
coglycan deficiency. This is consistent with the normal sta- 
tus of dystrophin and syntrophins in this disorder. 
Discussion 
A  principal  finding  of  this  work  is  that  assembly  of 
nNOS  into the dystrophin complex is dependent upon the 
normal structure of the rodlike domains ofdystrophin. Pre- 
vious analyses of specific protein contacts involved in main- 
tenance of the dystrophin complex have focused on protein 
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interactions at the NH 2- and COOH-temninal domains of 
dystrophin.  These  studies  identify  a  functional  F-actin 
binding site near the NHa-terminus  (7)  and binding sites 
for  13-dystroglycan and syntrophins in  the  COOH-termi- 
nal domain of dystrophin (10).  Understanding the mecha- 
nism for nNOS association with the dystrophin complex is 
important  because  nNOS  is  uniquely  absent  from  sarco- 
lemma in certain animal models of muscular dystrophy and 
in  certain  patients  with  BMD.  Absence  of sarcolemmal 
nNOS in mdx mouse expressing a dystrophin minigene in- 
dicates  a  role  for  the  rodlike  domain  of dystrophin  for 
binding  of nNOS.  Studies  of nNOS  expression  in  BMD 
patients demonstrate that distinct deletions in the NH2-ter- 
minal or central domain of dystrophin disrupt recruitment 
of nNOS  to  the  sarcolemma.  These  results indicate that a unique  nNOS  interaction domain may not be present in 
dystrophin, but that proper conformation is required for as- 
sembly ofnNOS into the dystrophin complex. 
Previous studies suggest that direct interaction of nNOS 
with 0d-syntrophin accounts for association of nNOS with 
the dystrophin complex (29). Three syntrophin genes have 
been identified and each contains two pleckstrin homology 
(PH) domains. The first PH domain is split by a PDZ mo- 
tif,  and the second PH  domain is followed by a COOH- 
terminal region unique to the syntrophins (38).  Interaction 
of nNOS with ~xl-syntrophin is mediated by direct associa- 
tion of PDZ protein-binding interfaces near the NH2-ter- 
minus of nNOS and cxl-syntrophin. Studies here are con- 
sistent with this model and demonstrate that &l-syntrophin, 
but not dystrophin, [3-dystroglycan or cl-sarcoglycan binds 
to the  PDZ-containing domain of nNOS.  NOS  isoforms 
lacking a PDZ motif do not associate  with the dystrophin 
complex,  further  suggesting  that  the  PDZ  domain  of 
nNOS represents the relevant domain for interaction (29). 
The  precise  binding  site(s)  for  syntrophins  within  the 
dystrophin complex is uncertain. In vitro studies show that 
the COOH-terminal region of syntrophin directly interacts 
with a splice-prone COOH-terminal domain ofdystrophin 
(39-41).  However, syntrophins are present in  dystrophin 
complexes  of the  A330  transgenic  mouse  that  lacks  the 
identified syntrophin interaction domain, suggesting addi- 
tional  bindings  sites  for  syntrophins  (35).  It  is  not  clear 
which domain of syntrophins might interact with these ad- 
ditional sarcolemmal binding sites. PH domains are known 
to interact with specific membrane proteins and phospho- 
lipids  (42),  and these regions of syntrophins represent can- 
didate interaction domains. Because the first PH domain of 
syntrophin is split  by the PDZ domain (38),  it is possible 
that sinmltaneous occupation of the PH1  and PDZ sites is 
sterically prohibited.  Therefore, membrane  association  of 
syntrophin  mediated  by  its  PH  domains  could  preclude 
binding of nNOS  to the PDZ  domain.  This may explain 
the observed sarcolemmal expression of syntrophin and ab- 
sence ofnNOS in certain disease states. 
nNOS appears not to interact with utrophin-containing 
complexes.  During  early  postnatal  muscle  development, 
nNOS  is not concentrated with complexes of cxl-syntro- 
phin  and  utrophin  at  neuromuscular endplates.  Similarly, 
utrophin  complexes  at  neuronmscular  endplates  of mdx 
mouse lack nNOS. Taken together with biochemical stud- 
ies  showing  direct interaction of nNOS  with Rl-syntro- 
phin in vitro, we propose that sarcolemmal localization of 
nNOS requires both syntrophin and dystrophin. It is alter- 
natively possible that nNOS primarily binds directly to dys- 
trophin in vivo. We have, however, been unable to detect 
direct interaction between nNOS  and dystrophin in vitro 
and would disfavor this model. Future studies ofnNOS ex- 
pression in mice lacking syntrophin isoforms may be neces- 
sary to definitively clarify this issue. 
Loss of sarcolemmal nNOS does not appear to be a ge- 
neric consequence of muscle disease, nNOS expression oc- 
curs normally at the sarcolemma in a variety of inflamma- 
tory, neuropathic, and idiopathic muscle disorders  (Chao, 
D.S., and D.S. Bredt, unpublished observations), and in dy 
mutant mice that have muscular dystrophy associated with 
loss  of extracellular M-laminin  (merosin;  28).  Three pa- 
tients with similar deletions of exons 45-47 of dystrophin 
all showed loss of sarcolemmal nNOS but exhibited a wide 
spectrum of clinical variability. This domain of dystrophin 
is apparently critical for assembly ofnNOS, and the clinical 
differences could be caused by environmental and/or epi- 
genetic factors, nNOS was expressed normally in two pa- 
tients with autosomal recessive muscular dystrophy due to 
mutations in oL-sarcoglycan (adhalin). Abnormality of nNOS 
expression, therefore, appears specific for dystrophin-related 
disease,  and  immunohistochernical analysis for nNOS  may 
provide a supplemental diagnostic test. 
Abnormal  expression of nNOS  may play a  role in  the 
pathophysiology of BMD. Decreased expression of nNOS 
alone is not sufficient to produce muscular dystrophy, as we 
have not detected muscle pathology in nNOS a/a mice that 
have a targeted disruption ofnNOS (Chao, D.S., and D.S. 
Bredt,  unpublished  observations).  However,  endogenous 
NO does play a role in regulation of skeletal muscle devel- 
opment and contractility (24,  26). Disruption of these NO 
signaling  pathways  may  contribute  to  abnormal  nmscle 
function  and  incomplete  myofiber regeneration  seen  in 
muscular dystrophy. In mdx mice expressing Dp71  or dys- 
trophin  minigene,  nNOS  is  the  only known  dystrophin- 
associated protein absent from the sarcolemnaa.  Transgenic 
mdx mice expressing the dystrophin minigene have an ex- 
tremely mild  muscular dystrophy characterized by only a 
modest increase in central nuclei and serum pyruvate kinase 
activity (20,  21). A human patient with an identical muta- 
tion had a mild dystrophy and was ambulatory with the aid 
of a  stick at  age  61  (43).  In  contrast  to  the  mild  clinical 
phenotype, this minigene mutation in a 25-year-old patient 
was  associated  with  severe  histopathological  nmscle  fiber 
atrophy, extensive replacement by fat and fibrous connec- 
tive tissue, and few surviving fibers of normal diameter (43). 
These findings may be relevant in designing therapies for 
DMD.  We find that nNOS  does not associate  with utro- 
phin-containing complexes, so that strategies  for upregula- 
tion ofutrophin in DMD would not be expected to restore 
sarcolemmal nNOS. Because of the large size of the dystro- 
phin protein, vectors for gene therapy may need to encode 
truncation mutants. Expression ofa minigene lacking exons 
17-48  of dystrophin fails to recruit nNOS  to sarcolemma 
of mdx  mouse  and  is  associated with  a very mild  Becket 
phenotype.  Complete rescue  of muscle  function  may re- 
quire replacement with dystrophin constructs that properly 
recruit nNOS to skeletal muscle membranes. 
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